# CURRENT_HOLDINGS

> Durable source of truth for the user's manually confirmed A-share holdings used by daily GenGe V3.1.1 holding review. This file does **not** connect to a broker and must only be updated from explicit user confirmation or user-provided transaction/position evidence.

## Confirmed holdings

Snapshot basis: user-provided broker position evidence through 2026-09-03 13:38 CST. The latest screenshot confirms an additional purchase of `603993 洛阳钼业`: total quantity increased from 600 to 800 shares, with 600 currently available and the newly purchased 200 shares unavailable intraday under T+1. `601318 中国平安`, `001316 润贝航科`, and `600406 国电南瑞` remain held. `603369 今世缘` and `600276 恒瑞医药` remain fully closed at 0 shares. Quantities and average costs below are treated as confirmed until the user reports a new buy/sell or provides newer position evidence.

| Code | Name | Quantity | Average cost (CNY) | Status | Evidence date |
| --- | --- | ---: | ---: | --- | --- |
| 601318 | 中国平安 | 300 | 57.1672 | HELD | 2026-09-03 |
| 603993 | 洛阳钼业 | 800 | 18.9753 | HELD | 2026-09-03 |
| 001316 | 润贝航科 | 200 | 26.0950 | HELD | 2026-09-03 |
| 600406 | 国电南瑞 | 200 | 23.1253 | HELD | 2026-09-03 |

## Recently closed positions

| Code | Name | Previous quantity | Previous average cost (CNY) | Exit evidence | Status | Evidence date |
| --- | --- | ---: | ---: | --- | --- | --- |
| 603369 | 今世缘 | 300 | 29.5003 | User explicitly confirmed on 2026-09-01 that the entire remaining position was sold and provided broker transaction evidence; latest confirmed portfolio evidence continues to omit it from current holdings | CLOSED | 2026-09-01 |
| 600276 | 恒瑞医药 | 100 | 46.4105 | Broker position screenshot showed quantity 0 and user explicitly confirmed the sale | CLOSED | 2026-08-31 |

> `603369 今世缘` and `600276 恒瑞医药` are no longer current holdings. Historical canonical decisions remain historical facts only and must not be projected onto the current portfolio. The next holdings reconciliation / finalized production cycle must consume the current 0-share state for both names and must not manufacture a new Formal Action for either closed position.

## Daily review contract

Every trading-day holding review must refresh price, filings/material events, industry drivers, hard-logic status and valuation evidence. Production version `GEN_GE_V3_1_1_PRODUCTION` requires LOW/INVALID valuation confidence to return HOLD_REVIEW and keeps Hard Gate FAIL -> EXIT. Never infer a transaction from price movement or a prior plan.

## Latest manual holdings update — 2026-09-03 13:38 CST

Latest broker position snapshot confirms:

- `601318 中国平安`: **300 shares**, average cost **57.1672 CNY**, all 300 shares available.
- `603993 洛阳钼业`: **800 shares**, average cost **18.9753 CNY**; **600 shares available**, confirming **200 shares were newly added today** and are not yet available intraday under T+1.
- `001316 润贝航科`: **200 shares**, average cost **26.0950 CNY**, all 200 shares available.
- `600406 国电南瑞`: **200 shares**, average cost **23.1253 CNY**, all 200 shares available.
- `603369 今世缘`: remains **0 shares / CLOSED**.
- `600276 恒瑞医药`: remains **0 shares / CLOSED**.

Displayed position values and market references at 13:38 CST are informational evidence only and must not be reused as fresh prices in later production decisions:

- `601318 中国平安`: market value **17,370.00 CNY**, displayed market price **57.9000 CNY**, floating P/L **+205.97 CNY (+1.28%)**.
- `603993 洛阳钼业`: market value **14,832.00 CNY**, displayed market price **18.5400 CNY**, floating P/L **-360.83 CNY (-2.29%)**.
- `001316 润贝航科`: market value **5,592.00 CNY**, displayed market price **27.9600 CNY**, floating P/L **+365.20 CNY (+7.15%)**.
- `600406 国电南瑞`: market value **4,502.00 CNY**, displayed market price **22.5100 CNY**, floating P/L **-130.35 CNY (-2.66%)**.

Current confirmed A-share holdings are therefore exactly **4 names / 1,500 shares total**: `601318 中国平安` 300, `603993 洛阳钼业` 800, `001316 润贝航科` 200, and `600406 国电南瑞` 200.

This manual portfolio update changes holdings state only. It does **not** convert the user's discretionary add into a canonical Formal ADD and does **not** alter the GenGe V3.1.1 frozen production contract, Confidence Gate, Hard Gate, BUY/SELL thresholds, SELL rationale gate, canonical authority, or no-auto-trade policy. Any finalized canonical produced before this holdings update remains historical with respect to the old `603993` 600-share quantity; current holding Formal actions must be reconciled against this 800-share state in the next authorized production cycle.

## Prior manual holdings update — 2026-09-01 13:33 CST

The prior broker position snapshot had confirmed:

- `601318 中国平安`: 300 shares at average cost 57.1676 CNY.
- `603993 洛阳钼业`: 600 shares at average cost 19.1087 CNY.
- `001316 润贝航科`: 200 shares at average cost 26.0950 CNY.
- `600406 国电南瑞`: 200 shares at average cost 23.1253 CNY.

That prior portfolio contained 4 names / 1,300 shares total and is superseded by the 2026-09-03 13:38 CST evidence above.

## Latest hourly risk review — 2026-08-26 20:09 CST

- Fresh-data invariant: accepted 2026-08-26 closes were recovered for `603369 今世缘` (28.10), `600276 恒瑞医药` (46.74) and `600406 国电南瑞` (23.42). A clean independently accepted 2026-08-26 exact close was not recovered for `001316 润贝航科`; price-dependent action on that name therefore remains fail-closed.
- `603369 今世缘`: **HOLD_REVIEW / NO ADD**. 2026H1 revenue 64.35亿 (-7.41%), attributable profit 20.82亿 (-6.60%), deduct-profit -5.77%; operating cash flow 16.16亿 (+50.31%). Structural baijiu demand/channel pressure remains material, but Q2 partial recovery and improved cash flow mean no new formal REDUCE/EXIT trigger. 2026-08-26 accepted close 28.10 CNY.
- `001316 润贝航科`: **HOLD**. 2026H1 revenue 5.73亿 (+21.97%), attributable profit 1.12亿 (+44.82%), deduct-profit +45.14%, operating cash flow 1.19亿 (+26.52%). The 2026-08-24 withdrawal of the convertible-bond application is noted but company filings state no material adverse operating/financial effect; no thesis-break evidence. Exact 2026-08-26 close remains unverified, so no price-dependent ADD/REDUCE.
- `600276 恒瑞医药`: **HOLD_REVIEW**. 2026-08-26 accepted close 46.74 CNY. H1 deduct-profit and operating-cash-flow deterioration remain the key watch items; latest 2026-08-25 drug marketing-application acceptance is pipeline-supportive, not a sell trigger. No newly verified evidence establishes a durable innovation-pipeline/moat break or formal REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD**. 2026-08-26 accepted close 23.42 CNY. No new material event falsifies grid digitization/UHV demand or grid-control/customer-certification moat; latest visible company item is the 2026H1 earnings-call notice. No REDUCE/EXIT trigger.
- **New REDUCE/EXIT:** NONE. **Holding thesis invalidation:** NONE newly established.

> The hourly risk review above is retained as historical audit evidence from 2026-08-26. It must not override later manual transaction evidence; `603369 今世缘` and `600276 恒瑞医药` are now CLOSED, while `601318 中国平安` and `603993 洛阳钼业` were added later and therefore are not covered by that historical review.

## Change history

- 2026-09-03 13:38 CST: updated from latest broker-position evidence. `603993 洛阳钼业` increased from **600 to 800 shares** after a new **200-share add**; average cost moved from **19.1087 to 18.9753 CNY** and only 600 shares are currently available, consistent with the new 200 shares being T+1 unavailable. Refreshed `601318 中国平安` displayed average cost to **57.1672 CNY**. Reconfirmed `001316 润贝航科` 200 at 26.0950 and `600406 国电南瑞` 200 at 23.1253. Current confirmed holdings remain 4 names but now total **1,500 shares**. This is a holdings-state update only and is not a canonical Formal ADD.
- 2026-09-01 13:33 CST: updated from broker-position evidence after user confirmed planned purchases were completed. Added `601318 中国平安` 300 shares at average cost 57.1676 CNY and `603993 洛阳钼业` 600 shares at average cost 19.1087 CNY. Reconfirmed `001316 润贝航科` 200 at 26.0950 and `600406 国电南瑞` 200 at 23.1253. `603369 今世缘` remained 0 / CLOSED. Current confirmed holdings were 4 names totaling 1,300 shares.
- 2026-09-01 CST: user explicitly confirmed the sale of the entire remaining `603369 今世缘` position and provided broker transaction evidence. Updated `603369 今世缘` from 300 shares to 0 / CLOSED.
- 2026-08-31 09:55 CST: updated from broker-position evidence. `600276 恒瑞医药` was explicitly sold by the user and is now 0 shares / CLOSED. Also refreshed displayed average costs from the latest screenshot.
- 2026-08-26 20:09 CST: refreshed all four then-confirmed holdings. Accepted same-day closes for 今世缘/恒瑞医药/国电南瑞; 润贝航科 exact close remained unavailable from independently accepted sources. No new REDUCE/EXIT or thesis invalidation.
- 2026-08-26 16:06 CST: hourly opportunity + holdings-risk refresh found no new REDUCE/EXIT trigger; price-dependent actions failed closed because a clean 2026-08-26 closing-price set was not independently accepted.
- 2026-08-26: GenGe V3.1.1 current-date dry-run returned HOLD_REVIEW / Confidence INVALID for all four then-confirmed holdings because refreshed normalized earnings, realistic/implied growth and neutral value were incomplete; no cost-basis or mechanical valuation sell was emitted.
- 2026-08-26: initialized from the latest recoverable broker-position evidence supplied by the user on 2026-08-25.
